InMed Pharmaceuticals Unveils Oral Alzheimer's Candidate, Shares Rise Tuesday – InMed Pharmaceuticals (NASDAQ:INM)

On Tuesday, Pharmaceutical company InMed Inc. INM confirmed INM-901 as an oral formulation to be used in its development programs for Alzheimer's disease.

Recent preclinical studies have proven that INM-901, a proprietary small molecule drug candidate, can be administered orally and achieve therapeutic levels in the brain comparable to those achieved through intraperitoneal or abdominal cavity (IP) injection, which is a common route of administration for preclinical research in neurodegenerative diseases.

The data indicate that the INM-901 formulation can be administered orally and maintains drug exposure levels similar to those of IP administration over a 24-hour period in the brain.

Michael WoudenbergInMed's Chief Operating Officer and Senior Vice President of Chemistry, Manufacturing and Controls, said, “We are excited by the recent data confirming that INM-901 can be delivered across the blood-brain barrier into brain tissue as an oral formulation providing significant advantages for further development of this compound in the treatment of Alzheimer's.”

“Similar drug levels in target tissue are not typically observed between oral and intraperitoneal administration. The supportive data generated by the oral formulation provide an attractive therapeutic approach, given the numerous challenges associated with drug delivery to the brain,” Woudenberg added.

Antibodies, which are large molecules, are difficult to formulate orally and present significant challenges for absorption in the gastrointestinal tract and subsequent delivery into the bloodstream; therefore, alternative administration methods, such as intravenous or subcutaneous injection, must be used.

INM-901 is a small molecule capable of achieving absorption from the gastrointestinal tract into the bloodstream and effectively penetrates the blood-brain barrier.

The Company is conducting further chemical, manufacturing and controls analyses for both the active substance and the drug product formulation, including drug metabolism studies, dose-ranging studies and pharmacokinetic studies to support the submission of an IND.

Price Action: INM shares were up 241.8% to $0.51 at last check Tuesday.

Read next:

Photo: Shutterstock